Medifast Statistics
Total Valuation
Medifast has a market cap or net worth of $124.99 million. The enterprise value is -$17.21 million.
| Market Cap | 124.99M |
| Enterprise Value | -17.21M |
Important Dates
The last earnings date was Monday, August 3, 2026, after market close.
| Earnings Date | Aug 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Medifast has 10.34 million shares outstanding. The number of shares has increased by 0.27% in one year.
| Current Share Class | 10.34M |
| Shares Outstanding | 10.34M |
| Shares Change (YoY) | +0.27% |
| Shares Change (QoQ) | +1.17% |
| Owned by Insiders (%) | 3.87% |
| Owned by Institutions (%) | 63.23% |
| Float | 7.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.40 |
| Forward PS | 0.45 |
| PB Ratio | 0.66 |
| P/TBV Ratio | 0.64 |
| P/FCF Ratio | 31.25 |
| P/OCF Ratio | 14.26 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.86, with a Debt / Equity ratio of 0.14.
| Current Ratio | 4.86 |
| Quick Ratio | 4.09 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | 6.88 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -12.42% and return on invested capital (ROIC) is -39.40%.
| Return on Equity (ROE) | -12.42% |
| Return on Assets (ROA) | -4.60% |
| Return on Invested Capital (ROIC) | -39.40% |
| Return on Capital Employed (ROCE) | -8.91% |
| Weighted Average Cost of Capital (WACC) | 6.63% |
| Revenue Per Employee | $834,034 |
| Profits Per Employee | -$67,374 |
| Employee Count | 380 |
| Asset Turnover | 1.20 |
| Inventory Turnover | 3.79 |
Taxes
In the past 12 months, Medifast has paid $11.63 million in taxes.
| Income Tax | 11.63M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.48% in the last 52 weeks. The beta is 0.70, so Medifast's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -1.48% |
| 50-Day Moving Average | 11.09 |
| 200-Day Moving Average | 11.19 |
| Relative Strength Index (RSI) | 65.44 |
| Average Volume (20 Days) | 210,022 |
Short Selling Information
The latest short interest is 1.64 million, so 15.86% of the outstanding shares have been sold short.
| Short Interest | 1.64M |
| Short Previous Month | 2.16M |
| Short % of Shares Out | 15.86% |
| Short % of Float | 21.02% |
| Short Ratio (days to cover) | 5.61 |
Income Statement
In the last 12 months, Medifast had revenue of $316.93 million and -$25.60 million in losses. Loss per share was -$2.32.
| Revenue | 316.93M |
| Gross Profit | 219.45M |
| Operating Income | -19.51M |
| Pretax Income | -13.97M |
| Net Income | -25.60M |
| EBITDA | -5.66M |
| EBIT | -19.51M |
| Loss Per Share | -$2.32 |
Balance Sheet
The company has $169.82 million in cash and $27.62 million in debt, with a net cash position of $142.20 million or $13.75 per share.
| Cash & Cash Equivalents | 169.82M |
| Total Debt | 27.62M |
| Net Cash | 142.20M |
| Net Cash Per Share | $13.75 |
| Equity (Book Value) | 196.38M |
| Book Value Per Share | 18.99 |
| Working Capital | 160.47M |
Cash Flow
In the last 12 months, operating cash flow was $8.79 million and capital expenditures -$4.78 million, giving a free cash flow of $4.01 million.
| Operating Cash Flow | 8.79M |
| Capital Expenditures | -4.78M |
| Depreciation & Amortization | 13.85M |
| Net Borrowing | n/a |
| Free Cash Flow | 4.01M |
| FCF Per Share | $0.39 |
Margins
Gross margin is 69.24%, with operating and profit margins of -6.15% and -8.08%.
| Gross Margin | 69.24% |
| Operating Margin | -6.15% |
| Pretax Margin | -4.41% |
| Profit Margin | -8.08% |
| EBITDA Margin | -1.79% |
| EBIT Margin | -6.15% |
| FCF Margin | 1.27% |
Dividends & Yields
Medifast does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.27% |
| Shareholder Yield | -0.27% |
| Earnings Yield | -20.41% |
| FCF Yield | 3.20% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medifast has an Altman Z-Score of 3.7 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.7 |
| Piotroski F-Score | 3 |